Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 2Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 87Breast Neoplasms 49Prostatic Neoplasms 42Squamous Cell Carcinoma of Head and Neck 34Lung Neoplasms 24Neoplasms 19Stomach Neoplasms 18Head and Neck Neoplasms 17Neoplasm Metastasis 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Urinary Bladder Neoplasms 13Carcinoma, Transitional Cell 11Triple Negative Breast Neoplasms 10Ovarian Neoplasms 8Endometrial Neoplasms 8Carcinoma, Squamous Cell 8Adenocarcinoma 8Non-Muscle Invasive Bladder Neoplasms 7HER2-positive Breast Cancer 7Melanoma 6Carcinoma 6Small Cell Lung Carcinoma 5Prostatic Neoplasms, Castration-Resistant 5Nasopharyngeal Carcinoma 5Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 5Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × Docetaxel × 1 year × Clear all
NCT06551324 2026-05-05

MEVPRO-1

Pfizer

Phase 3 Active not recruiting
600 enrolled
Genitourinary

Prostatic Neoplasms, Recurrence

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Shanghai Miracogen Inc.

Phase 2 Active not recruiting
238 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06976190 2026-01-20

Magic-C002

Shanghai Miracogen Inc.

Phase 3 Recruiting
446 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡